Polaryx Therapeutics, Inc. Common Stock (PLYX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Polaryx Therapeutics, Inc. Common Stock (PLYX) has a cash flow conversion efficiency ratio of -0.326x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.49 Million) by net assets ($4.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Polaryx Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Polaryx Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PLYX total liabilities for a breakdown of total debt and financial obligations.
Polaryx Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Polaryx Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AN2 Therapeutics Inc
NASDAQ:ANTX
|
-0.099x |
|
Media Capital
LS:MCP
|
-0.014x |
|
1-800 FLOWERS.COM Inc
NASDAQ:FLWS
|
-0.665x |
|
CareRx Corp
TO:CRRX
|
0.057x |
|
Soechi Lines Tbk
JK:SOCI
|
0.031x |
|
Zinus Inc
KO:013890
|
0.040x |
|
TS Corporation
KO:001790
|
0.047x |
|
Gozde Girisim Sermayesi Yatirim Ortakligi AS
IS:GOZDE
|
0.120x |
Annual Cash Flow Conversion Efficiency for Polaryx Therapeutics, Inc. Common Stock (2023–2025)
The table below shows the annual cash flow conversion efficiency of Polaryx Therapeutics, Inc. Common Stock from 2023 to 2025. For the full company profile with market capitalisation and key ratios, see Polaryx Therapeutics, Inc. Common Stock (PLYX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.57 Million | $-3.94 Million | -0.864x | -58.22% |
| 2024-12-31 | $4.71 Million | $-2.57 Million | -0.546x | -303.07% |
| 2023-12-31 | $1.28 Million | $-173.00K | -0.135x | -- |
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-… Read more